State-of-the-Art Dermatology in Spain

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (30 September 2025) | Viewed by 968

Special Issue Editors


E-Mail Website
Guest Editor
Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Avda. del Conocimiento s/n, 18016 Granada, Spain
Interests: mechanisms of immunopathology in allergic contact dermatitis; new diagnostic approaches for ACD; emerging allergens and their clinical relevance; genetic and epigenetic factors influencing susceptibility to ACD; comorbidities associated with ACD (e.g., atopic dermatitis, psoriasis); role of microbiome in ACD pathogenesis; advances in patch testing techniques and interpretation; occupational and environmental risk factors for ACD; innovations in prevention and management strategies; biomarkers for prognosis and monitoring in ACD; impact of ACD on quality of life and psychosocial health; emerging therapeutic targets and novel treatments
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue entitled “State-of-the-Art Dermatology in Spain” aims to highlight the latest advances, challenges, and innovations in dermatological research and clinical practice in Spain. This Special Issue will feature original research and comprehensive reviews on emerging therapies, diagnostic techniques, and the evolving landscape of dermatological diseases, with a particular focus on translational medicine and personalized treatment approaches.

Dr. Francisco José Navarro-Triviño
Dr. Ricardo Ruiz-Villaverde
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • dermatological research
  • dermatology
  • skin disease
  • psoriasis
  • atopic dermatitis
  • urticaria
  • alopecia areata

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1299 KB  
Review
Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review
by Francisco José Navarro Triviño, Juan Pablo Velasco Amador and Irene Rivera Ruiz
Biomedicines 2025, 13(10), 2458; https://doi.org/10.3390/biomedicines13102458 - 9 Oct 2025
Viewed by 716
Abstract
Background: Seborrheic dermatitis (SD) is a chronic, recurrent inflammatory dermatosis that primarily affects seborrheic areas such as the scalp, face, and upper trunk. Its etiology is multifactorial, involving sebaceous gland activity, immune dysregulation, skin barrier dysfunction, and alterations in the microbiome, particularly [...] Read more.
Background: Seborrheic dermatitis (SD) is a chronic, recurrent inflammatory dermatosis that primarily affects seborrheic areas such as the scalp, face, and upper trunk. Its etiology is multifactorial, involving sebaceous gland activity, immune dysregulation, skin barrier dysfunction, and alterations in the microbiome, particularly an overgrowth of Malassezia spp. Objective: This review provides an updated overview of the pathophysiological mechanisms of seborrheic dermatitis and critically examines current therapies and emerging treatments. Methods: A narrative review of the recent literature was conducted, including preclinical studies, clinical trials, and real-world evidence regarding SD pathogenesis and therapy. Special attention was paid to molecular pathways, microbiome-modulating strategies, and novel therapeutic agents. Results: Advances in transcriptomic and microbiome profiling have revealed a complex immunoinflammatory environment in SD, involving predominantly Th1, Th17, and Th22 axes. Conventional therapies are mainly based on antifungals, topical corticosteroids, and calcineurin inhibitors. However, new therapeutic approaches are under investigation, including PDE4 inhibitors (roflumilast, crisaborole, and apremilast), topical and oral JAK inhibitors, probiotics, and microbiome-targeted therapies. These agents offer promising results in selected patients, particularly those with refractory disease or facial involvement. Conclusions: SD remains a challenging condition due to its relapsing course and limited long-term therapeutic options. Emerging therapies represent a valuable opportunity to address unmet clinical needs, particularly in patients with severe, recurrent, or treatment-resistant forms. Full article
(This article belongs to the Special Issue State-of-the-Art Dermatology in Spain)
Show Figures

Figure 1

Back to TopTop